For nonhospitalized patients with symptomatic mild-to-moderate COVID-19 and a high risk for progression, risk for all-cause hospitalization or death is reduced with sotrovimab versus placebo, according to a study published online March 14 in the Journal of the American Medical Association.
Sotrovimab may prevent progression to severe COVID-19
For nonhospitalized patients with symptomatic mild-to-moderate COVID-19 and a high risk for progression, risk for all-cause hospitalization or death is reduced with sotrovimab versus placebo, according to a study published online March 14 in the Journal of the American Medical Association.